Sofamor Danek paying up to $50 mil. for Genetics Institute's rhBMP-2 for spinal fusion.
This article was originally published in The Gray Sheet
Executive SummarySOFAMOR DANEK TO DEVELOP GENETICS INSTITUTE'S rhBMP-2 FOR SPINAL FUSION under a collaborative alliance announced Feb. 16. With the deal, Sofamor Danek is gaining exclusive North American rights to develop and commercialize products based on Genetics Institute's recombinant human bone morphogenetic protein to induce bone growth in spinal reconstruction procedures.
You may also be interested in...
Health ministers have called for more action on access to medicines, including a new EU work agenda, rebuilding Europe’s manufacturing capabilities, further action on pricing, and greater leeway for member states to mitigate drug shortages by restricting parallel exports.
China’s Bio-Thera Solutions has received approval from the country’s NMPA to launch a Phase I clinical study comparing the pharmacokinetics and safety of its proposed ustekinumab biosimilar to Johnson & Johnson’s blockbuster psoriasis drug Stelara, the latest in a string of the biotech company’s products to advance into clinical development.